These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

577 related articles for article (PubMed ID: 18410249)

  • 1. Structural biology of the tumor suppressor p53.
    Joerger AC; Fersht AR
    Annu Rev Biochem; 2008; 77():557-82. PubMed ID: 18410249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural biology of the tumor suppressor p53 and cancer-associated mutants.
    Joerger AC; Fersht AR
    Adv Cancer Res; 2007; 97():1-23. PubMed ID: 17419939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome.
    Sigal A; Rotter V
    Cancer Res; 2000 Dec; 60(24):6788-93. PubMed ID: 11156366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer-associated p53 tetramerization domain mutants: quantitative analysis reveals a low threshold for tumor suppressor inactivation.
    Kamada R; Nomura T; Anderson CW; Sakaguchi K
    J Biol Chem; 2011 Jan; 286(1):252-8. PubMed ID: 20978130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural and sequential context of p53: A review of experimental and theoretical evidence.
    Saha T; Kar RK; Sa G
    Prog Biophys Mol Biol; 2015 Mar; 117(2-3):250-263. PubMed ID: 25550083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Computational protein chemistry of p53 and p53 peptides.
    Brandt-Rauf PW; Rosal RV; Fine RL; Pincus MR
    Front Biosci; 2004 Sep; 9():2778-87. PubMed ID: 15353313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The tumor suppressor gene p53 (part one). Structure, function and mechanisms of inactivation].
    Martin A
    Ann Pathol; 1995; 15(3):178-83. PubMed ID: 7639853
    [No Abstract]   [Full Text] [Related]  

  • 8. Structural basis for gene activation by p53 family members.
    Scoumanne A; Harms KL; Chen X
    Cancer Biol Ther; 2005 Nov; 4(11):1178-85. PubMed ID: 16294021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular "rehabilitation" by rational drug targeting: the challenge of P53 in cancer treatment.
    Tzatsos A; Papavassiliou AG
    Anticancer Res; 1999; 19(5B):4353-6. PubMed ID: 10628400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations.
    Suad O; Rozenberg H; Brosh R; Diskin-Posner Y; Kessler N; Shimon LJ; Frolow F; Liran A; Rotter V; Shakked Z
    J Mol Biol; 2009 Jan; 385(1):249-65. PubMed ID: 18996393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gain-of-function mutations in the tumor suppressor gene p53.
    van Oijen MG; Slootweg PJ
    Clin Cancer Res; 2000 Jun; 6(6):2138-45. PubMed ID: 10873062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strategies for manipulating the p53 pathway in the treatment of human cancer.
    Hupp TR; Lane DP; Ball KL
    Biochem J; 2000 Nov; 352 Pt 1(Pt 1):1-17. PubMed ID: 11062053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor suppressive functions of p53.
    Zilfou JT; Lowe SW
    Cold Spring Harb Perspect Biol; 2009 Nov; 1(5):a001883. PubMed ID: 20066118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Crystal structure of a superstable mutant of human p53 core domain. Insights into the mechanism of rescuing oncogenic mutations.
    Joerger AC; Allen MD; Fersht AR
    J Biol Chem; 2004 Jan; 279(2):1291-6. PubMed ID: 14534297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dynamic perspectives into the mechanisms of mutation-induced p53-DNA binding loss and inactivation using active perturbation theory: Structural and molecular insights toward the design of potent reactivators in cancer therapy.
    Olotu FA; Soliman MES
    J Cell Biochem; 2019 Jan; 120(1):951-966. PubMed ID: 30160791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Tumor suppressor gene p53: mechanisms of action in cell proliferation and death].
    Mendoza-Rodríguez CA; Cerbón MA
    Rev Invest Clin; 2001; 53(3):266-73. PubMed ID: 11496714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biological significance of a small highly conserved region in the N terminus of the p53 tumour suppressor protein.
    Liu WL; Midgley C; Stephen C; Saville M; Lane DP
    J Mol Biol; 2001 Nov; 313(4):711-31. PubMed ID: 11697899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural biology of the p53 tumour suppressor.
    Okorokov AL; Orlova EV
    Curr Opin Struct Biol; 2009 Apr; 19(2):197-202. PubMed ID: 19286366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural basis of DNA recognition by p53 tetramers.
    Kitayner M; Rozenberg H; Kessler N; Rabinovich D; Shaulov L; Haran TE; Shakked Z
    Mol Cell; 2006 Jun; 22(6):741-753. PubMed ID: 16793544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Relevance of p53 protein and its mutations for novel strategies in cancer therapy].
    Müller P; Nenutil R; Vojtĕsek B
    Cas Lek Cesk; 2004; 143(5):313-7. PubMed ID: 15305766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.